Loading company…
Aarhus-based STipe Therapeutics develops cancer treatments that target the STING pathway of the innate immune system.
Founded in 2018 in Aarhus, Denmark, STipe Therapeutics develops cancer therapies that target protein-protein interactions in the STING pathway. Led by CEO Claus Olesen, the company raised EUR 20 million in Series A funding in September 2019, co-led by Arix Bioscience and Novo Holdings, with other investors. Its products target oncologists and healthcare institutions, mainly in North America and Europe. It earns revenue through collaborations with pharmaceutical firms and research institutions.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in